Complaints of reported EpiPen failures has Mylan on defensive again

Mylan, the drug company that created outrage with the dramatic price increase of the EpiPen, is on the defensive again. A new report shows a big rise in complaints about the device not working in life-threatening emergencies.Bloomberg says 228 people this year reported failures of EpiPen, which injects a drug that can stop severe allergic reactions. That's way up from 2012 when just four failures were reported.Mylan doesn't take issue with the data but said Bloomberg's article is "misleading." I